Key Takeaways
- Record profit in a demand downturn: Galaxy posted its best-ever financial performance despite a 50% feedstock correction and demand cutbacks in developed markets, crediting astute risk management and mix execution.
- Volume growth returns as the priority: After three years of flat volumes, management is pivoting to sustainable volume-led growth, guiding 6–8% global consolidated volume growth with India structurally at 8–10%.
- Developed-market demand is split-timing: U.S. destocking should resolve by end-Q1 FY24, but European pain will be longer as consumers trade down to mass and masstige products.
- Specialty care took a triple hit: Freight cost normalization, prestige-to-mass trade-down, and destocking compressed specialty revenue and realization, a headwind that should ease as U.S. demand returns from Q2.
- What to watch next quarter: Whether U.S. demand actually returns from Q2 as customers indicate, the pace of Egypt and AMET stabilization, and how the contested anti-dumping duty on lauric acid plays out.
Demand Environment
- India structural story: Premium consumption uptick, rural demand revival, and a new entrant in home and personal care support a structural 8–10% volume growth trajectory over 3–5 years, with urban demand the major driver so far.
- U.S. destocking near its end: Inventory corrections across the pipeline from retailers to customers have run for six months; customer discussions point to destocking completing by end of this quarter, with demand returning from Q2 FY24.
- Europe trade-down pain: Underlying demand cutback is pushing consumers toward mass and masstige products, reducing the consumption frequency of premium products that use specialty ingredients; management expects this pain to persist longer than in the U.S.
- AMET stabilizing: Africa, Middle East, Turkey has been a concern for two years due to currency devaluation and inflation; currencies have been stable for two months, and Egypt and Turkey are showing signs of stability, with Egypt growth expected back by H2 FY24.
- Recession risk contained: U.S. customers indicate any recession would be shorter and shallower; the main near-term risk flagged is the debt ceiling resolution.
Natarajan Krishnan: "Recession, as our customers say that it can be like for a shorter time and at a lower level. That's what they indicate even if that happens, but the main issue is in terms of they have to resolve this debt ceiling stuff."
Specialty Care: The Drag & Recovery Path
- Triple compression on revenue: Specialty care revenue declined because freight rates into Europe and the U.S. corrected sharply (down 100–150%), reducing top-line pass-through; inflation pushed consumers from prestige toward mass products, hitting specialty ingredient demand; and destocking unwound inventory built up on expectations of continued robust demand.
- Mix hurt realization: The product mix within specialty was unfavorable for better realization, compounding the volume pressure.
- Recovery sequencing: U.S. customers are more bullish about improvement from next quarter; Europe should start coming back from the end of the first half; the U.S. would probably start reflecting from the beginning of the second quarter.
- Tri-K innovation push: The company fortified its product portfolio with new innovations targeting Indie brands and small customers, launching multifunctional products for various end-use benefit combinations.
Margin & Mix Execution
- EBITDA per tonne rose despite headwinds: The increase was driven by favorable product mix within both specialty and performance surfactants, judicious cost and raw-material position management, and better pricing ability in certain markets.
- Performance surfactants mix advantage: Mix within performance products (various SLS and SLES grades, solid vs liquid forms) plus the ability to manage risk positions in fatty alcohol led to better realization, even as some surfactant prices like alcohol ethoxylates declined 20% QoQ while fatty alcohol stayed flattish.
- Other expenditure fell on freight: The decline in other expenditure was mainly due to the fall in freight costs; power and fuel costs were slightly inflationary and not a source of reduction.
- Fatty alcohol outlook benign: Barring weather-related supply issues from El Nino, demand appears tepid and prices should remain flattish with no great spikes expected.
Anti-Dumping Duty on Lauric Acid
- What happened: India imposed an anti-dumping duty on lauric acid imports two weeks before the call; the duty applies only to imports for domestic supplies, not to imports catering to export business.
- Management stance: The company is contesting the levy heavily and intensely with the Directorate General of Trade Remedies, reviewing the notification and discussing with its legal team to initiate all remedies available under law.
- Pass-through mechanism: Management stated clearly that any such levies will ultimately get passed on to consumers, with temporary perturbations as the market adjusts to a new equilibrium; the impact will be felt only if end consumers bear the brunt.
Unnathan Shekhar: "So it's not that we have just accepted it because any such levy, which is inflationary, is something that we need to contest, and we firmly believe this is unjust."
Regional & Segment Dynamics
| Region / Segment | Trend | Commentary |
|---|---|---|
| India | ▲ Strong | Majorly tilted toward mass and masstige; rural demand making a comeback; urban remains the major growth portion; new HPC entrant adds tailwind. |
| Performance Surfactants | ▲ 12% volume growth | Largely driven by domestic India; mix and risk management supported realization. |
| AMET ex-Egypt | ▬ Stabilizing | 7% volume growth momentum sustaining; currency stability emerging after two years of pressure. |
| Egypt | ▼ Weak, recovering | Volumes stabilizing; growth expected back by H2 FY24. |
| U.S. | ▼ Weak, near-turn | Six months of destocking nearing end; demand expected from Q2 FY24. |
| Europe | ▼ Weak, prolonged | Consumer trade-down to mass/masstige products; pain will be longer. |
| Specialty Care | ▼ Declined | Triple hit from freight, trade-down, and destocking; U.S.-led recovery expected from Q2. |
Unnathan Shekhar: "Whereas in the U.S., we would like to believe that the inventory destocking, which has been going on for the last almost 6 months, will likely stop by the end of this quarter... The pain, we believe, in Europe will be longer."
Capex & Capacity
- Annual capex run-rate: INR150–170 crores for next year, with clear plans for capacity additions and infrastructure requirements across both performance and specialty ingredients.
- Capacity trigger: When utilization reaches 80%, the company starts thinking about new capex.
- Planning horizons: Specialty ingredients capex is planned on a 7–8 year horizon; performance surfactants on about a 4-year horizon.
- Performance-to-specialty mix: The proportion will continue to remain around the two-thirds, one-third zone.
- Ethoxylates selectivity: The company is very selective in the ethoxylates it makes and sells; a large part goes for captive consumption, and it is not a general ethoxylate market player.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| India volume growth | 8% to 10% across segments | Next 3 to 5 years |
| Global consolidated volume growth | 6% to 8% | Ongoing |
| EBITDA growth | Higher than volume growth | Ongoing |
| PAT growth | Higher than EBITDA growth | Ongoing |
| ROCE | In the 22% zone | Ongoing |
| U.S. demand recovery | Destocking ends, demand returns | Q2 FY24 |
| Egypt growth recovery | Growth should come back | H2 FY24 |
| Annual capex | INR150–170 crores | FY24 |
| Performance-to-specialty proportion | Around 2/3, 1/3 zone | Ongoing |
| Anti-dumping duty on lauric acid | Any levies will finally get passed on to consumers | When equilibrium establishes |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Volume growth target (global consolidated) | 6% to 8% |
| Volume growth target (India domestic, 3-5 year outlook) | 8% to 10% |
| Performance surfactants volume growth | 12% for the quarter |
| AMET region volume growth (ex-Egypt) | 7% |
| Performance to specialty volume proportion | 2/3, 1/3 |
| Specialty care revenue | roughly INR245 crores, down from INR400 crores in Q3 |
| Other expenditure | INR117 crores, down from INR147 crores in Q1, majorly due to freight cost reduction |
| Lauryl alcohol price | $1,350 to $1,400 per tonne, down from $2,000–$2,200 in early FY23 |
| Fatty alcohol price correction (last 12 months) | 50% |
| Fatty alcohol price change (Q4 vs Q3) | flat |
| Fatty alcohol as share of raw material purchases | 50% to 55% |
| ROCE target | 22% zone |
| Maintenance capex | ₹30 crores to ₹40 crores per annum |
| Capex guidance | ₹150 crores per annum, or roughly ₹150 crores to ₹170 crores for the next year |
| Cash and bank balance | almost INR150 crores |
| Total trading capacity | 440,000 tonnes |
| FY23 volumes | around 220,000 tonnes |
| Average capacity utilization | about 65% |
| EBITDA per tonne increase (from prior average) | from INR16,000–INR17,000 to around INR24,000–INR25,000 |
| Performance surfactants realization (per an analyst's math) | about INR115 per kg (based on FY21 levels) |
| Specialty care realization (per an analyst's math) | INR140 to INR150 |